Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2016
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
Ying Cheng, Haruyasu Murakami, Pan-Chyr Yang, et al.
Breast Cancer (Tokyo, Japan)
|
February 23, 2012
A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up
Pramod K Julka, Raju T Chacko, Shona Nag, et al.
Targeted Oncology
|
June 17, 2023
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
Chao-Hua Chiu, Meng-Chih Lin, Yu-Feng Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2024
CNS Protective Effect of Selpercatinib in First-Line <i>RET</i> Fusion-Positive Advanced Non-Small Cell Lung Cancer
Maurice Pérol, Benjamin J Solomon, Koichi Goto, et al.
JTO Clinical and Research Reports
|
September 22, 2025
First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With <i>RET</i> Fusion-Positive NSCLC: A LIBRETTO-431 Subgroup Analysis
Koichi Goto, Herbert H Loong, Caicun Zhou, et al.
Advances in Therapy
|
May 23, 2026
Outcomes of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer Treated with First-Line Non-Molecularly Targeted Therapies: A Real-World Benchmark in Europe from the RECALIB-RET Study
Luis León-Mateos, Maximillian J Hochmair, Amparo Sánchez-Gastaldo, et al.
Applied Health Economics and Health Policy
|
May 11, 2026
Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26
Jessica E Forsyth, Monika Achra, Javier Baena Espinar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 13, 2019
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
James Chih-Hsin Yang, Ying Cheng, Haruyasu Murakami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2022
Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2024
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC
Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2016
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
Ying Cheng, Haruyasu Murakami, Pan-Chyr Yang, et al.
Breast Cancer (Tokyo, Japan)
|
February 23, 2012
A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up
Pramod K Julka, Raju T Chacko, Shona Nag, et al.
Targeted Oncology
|
June 17, 2023
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
Chao-Hua Chiu, Meng-Chih Lin, Yu-Feng Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2024
CNS Protective Effect of Selpercatinib in First-Line <i>RET</i> Fusion-Positive Advanced Non-Small Cell Lung Cancer
Maurice Pérol, Benjamin J Solomon, Koichi Goto, et al.
JTO Clinical and Research Reports
|
September 22, 2025
First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With <i>RET</i> Fusion-Positive NSCLC: A LIBRETTO-431 Subgroup Analysis
Koichi Goto, Herbert H Loong, Caicun Zhou, et al.
Advances in Therapy
|
May 23, 2026
Outcomes of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer Treated with First-Line Non-Molecularly Targeted Therapies: A Real-World Benchmark in Europe from the RECALIB-RET Study
Luis León-Mateos, Maximillian J Hochmair, Amparo Sánchez-Gastaldo, et al.
Applied Health Economics and Health Policy
|
May 11, 2026
Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26
Jessica E Forsyth, Monika Achra, Javier Baena Espinar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 13, 2019
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis
James Chih-Hsin Yang, Ying Cheng, Haruyasu Murakami, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 19, 2022
Selpercatinib in Patients With <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
Alexander Drilon, Vivek Subbiah, Oliver Gautschi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 2, 2024
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC
Kazuhiko Nakagawa, Edward B Garon, Takashi Seto, et al.
Page
of 6